Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by KingWhatsion Nov 10, 2010 11:32am
295 Views
Post# 17686647

RE: RE: RE: RE: weird that BWN hasnt dropped with

RE: RE: RE: RE: weird that BWN hasnt dropped withMy comment wasn't about the company trading shares only about a recent loan. The insider comment hinted that maybe the lender was a friend of company management and got a hell of a deal for his 1 year loan - around 600 thousand bucks.

I was speaking specifically of this news release...

TORONTO, ONTARIO, Oct. 7, 2010 (Marketwire) -- Brownstone Ventures Inc.(TSX VENTURE:BWN) ("Brownstone") announces that it has closed itspreviously announced term loan, whereby it has obtained $3,000,000 infinancing in the form of a secured loan. The loan, provided by 2256629Ontario Ltd., an arm's length private company, is for a one-year term(subject to prepayment) and bears interest at a rate of 12% p.a.,payable monthly. The Company's obligations under the loan are secured bya charge over its personal property. As consideration for the loan,Brownstone paid a cash bonus of $300,000 and a facility fee of $30,000to the lender.

Proceeds from the loan will be used for working capital purposes.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities